TITLE

A genome-wide association study on androstenone levels in pigs reveals a cluster of candidate genes on chromosome 6

AUTHOR(S)
Duijvesteijn, Naomi; Knol, Egbert F.; Merks, Jan W. M.; Crooijmans, Richard P. M. A.; Groenen, Martien A. M.; Bovenhuis, Henk; Harlizius, Barbara
PUB. DATE
January 2010
SOURCE
BMC Genetics;2010, Vol. 11, p42
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In many countries, male piglets are castrated shortly after birth because a proportion of un-castrated male pigs produce meat with an unpleasant flavour and odour. Main compounds of boar taint are androstenone and skatole. The aim of this high-density genome-wide association study was to identify single nucleotide polymorphisms (SNPs) associated with androstenone levels in a commercial sire line of pigs. The identification of major genetic effects causing boar taint would accelerate the reduction of boar taint through breeding to finally eliminate the need for castration. Results: The Illumina Porcine 60K+SNP Beadchip was genotyped on 987 pigs divergent for androstenone concentration from a commercial Duroc-based sire line. The association analysis with 47,897 SNPs revealed that androstenone levels in fat tissue were significantly affected by 37 SNPs on pig chromosomes SSC1 and SSC6. Among them, the 5 most significant SNPs explained together 13.7% of the genetic variance in androstenone. On SSC6, a larger region of 10 Mb was shown to be associated with androstenone covering several candidate genes potentially involved in the synthesis and metabolism of androgens. Besides known candidate genes, such as cytochrome P450 A19 (CYP2A19), sulfotransferases SULT2A1, and SULT2B1, also new members of the cytochrome P450 CYP2 gene subfamilies and of the hydroxysteroid-dehydrogenases (HSD17B14) were found. In addition, the gene encoding the β-chain of the luteinizing hormone (LHB) which induces steroid synthesis in the Leydig cells of the testis at onset of puberty maps to this area on SSC6. Interestingly, the gene encoding the a-chain of LH is also located in one of the highly significant areas on SSC1. Conclusions: This study reveals several areas of the genome at high resolution responsible for variation of androstenone levels in intact boars. Major genetic factors on SSC1 and SSC6 showing moderate to large effects on androstenone concentration were identified in this commercial breeding line of pigs. Known and new candidate genes cluster especially on SSC6. For one of the most significant SNP variants, the difference in the proportion of animals surpassing the threshold of consumer acceptance between the two homozygous genotypes was as much as 15.6%.
ACCESSION #
51944136

 

Related Articles

  • Characterization of Nestin-positive stem Leydig cells as a potential source for the treatment of testicular Leydig cell dysfunction. Jiang, Mei Hua; Jiao, Jianwei; Xiang, Andy Peng; Cai, Bing; Tuo, Ying; Wang, Jiancheng; Li, Guilan; Zhang, Min; Lahn, Bruce T; Zang, Zhi Jun; Tu, Xiang'an; Wan, Zi; Deng, Chunhua; Gao, Yong; Su, Zhijian; Li, Weiqiang // Cell Research;Dec2014, Vol. 24 Issue 12, p1466 

    The ability to identify and isolate lineage-specific stem cells from adult tissues could facilitate cell replacement therapy. Leydig cells (LCs) are the primary source of androgen in the mammalian testis, and the prospective identification of stem Leydig cells (SLCs) may offer new opportunities...

  • Successful testicular sperm recovery and IVF treatment in a man with Leydig cell hypoplasia. Bakircioglu, M.; Tulay, P.; Findikli, N.; Erzik, B.; Gultomruk, M.; Bahceci, M. // Journal of Assisted Reproduction & Genetics;Jul2014, Vol. 31 Issue 7, p817 

    No abstract available.

  • Degarelix in the Treatment of Prostate Cancer. Ercole, Barbara; Thompson Jr., Ian M. // Clinical Medicine Reviews in Oncology;May2010, Issue 2, p189 

    Manipulation of the hypothalamic-pituitary-gonadal axis via androgen deprivation therapy has been in use since the 1940's for the treatment of advanced prostate cancer. Androgen deprivation may be achieved via surgical castration or pharmacological castration. Pharmacological castration is...

  • Partial orchiectomy and testis intratubular germ cell neoplasia: World literature review. Bazzi, Wassim M.; Raheem, Omer A.; Stroup, Sean P.; Kane, Christopher J.; Derweesh, Ithaar H.; Downs, Tracy M. // Urology Annals;Sep2011, Vol. 3 Issue 3, p115 

    Approximately 5% of all patients diagnosed with testicular cancer may have contralateral intratubular germ cell neoplasia (ITGCN) and may develop contralateral germ cell tumor. Here, we present a historical review and current literature regarding ITGCN and partial orchiectomy. The PubMed world...

  • Venous sampling can be crucial in identifying the testicular origin of idiopathic male luteinising hormone-independent sexual precocity. Richter-Unruh, Annette; Jorch, Norbert; Wessels, Hendrika T.; Weber, Ernst A.; Hauffa, Berthold P. // European Journal of Pediatrics;2002, Vol. 161 Issue 12, p668 

    It has been recently shown that male LHindependent sexual precocity is caused by a somatic activating mutation in the luteinising hormone receptor (LHR) of Leydig cell tumours. In each of the patients described to date, the tumour was a well-defined, single encapsulated nodule. We present a...

  • hypoleydigism.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1136 

    A definition of the term "hypoleydigism," which refers to a decreased secretion of androgen by the Leydig cells of the testicles, is presented.

  • Intermittent ADT in Prostate Cancer: A Step-by-Step Approach. GOMELLA, LEONARD G. // Renal & Urology News;Sep2011, Vol. 10 Issue 9, p21 

    The article discusses a step-by-step approach for intermittent androgen deprivation therapy (ADT) in prostate cancer. It mentions the primary goal of ADT which is the pharmacologic suppression of gonadal testosterone production with medical castration and is achieved with either luteinizing...

  • Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. Gillessen, Silke; Templeton, Arnoud; Marra, Giancarlo; Yong-Fang Kuo; Valtorta, Emanuele; Shahinian, Vahakn B. // JNCI: Journal of the National Cancer Institute;Dec2010, Vol. 102 Issue 23, p1760 

    Background Androgen deprivation with gonadotropin-releasing hormone (GnRH) agonists or orchiectomy is a common but controversial treatment for prostate cancer. Uncertainties remain about its use, particularly with increasing recognition of serious side effects. In animal studies, androgens...

  • Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors. Guyader, Charlotte; Céraline, Jocelyn; Gravier, Eléonore; Morin, Aurélie; Michel, Sandrine; Erdmann, Eva; De Pinieux, Gonzague; Cabon, Florence; Bergerat, Jean-Pierre; Poupon, Marie-France; Oudard, Stéphane; Agoulnik, Irina // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape -frequency and delay- are influenced by hormone therapy modalities. More, hormone therapies induce crucial biological changes involving androgen receptors; some...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics